Hyprevention sas
PTIB – Hôpital Xavier Arnozan
Avenue du Haut-Lévêque
33604 PESSAC Cedex
France
Tél: +33(0)5 57 10 28 52
Fax: +33(0)5 67 07 10 26
DISTRIBUTION
FRANCE
PTIB – Hôpital Xavier Arnozan
Avenue du Haut-Lévêque
33600 PESSAC – France
Tél: +33(0)5 57 10 28 52
Fax: +33(0)5 67 07 10 26
Email: adv@hyprevention.com
www.hyprevention.com
ITALY
Bimar Ortho Srl
Via Riccardo Felici, 11
37135 VERONA – Italia
Tél: +39 045 8342591
Email: info@bimarortho.com
www.bimarortho.com
SWITZERLAND
SPINE SURGICAL GmbH
Bernstrasse 162
3052 Zollikofen – Suisse
Tél: +41(0)79 459 66 08
Email: office@spinesurgical.ch
www.spinesurgical.ch
ISRAËL
GAD MEDICAL
Brodetsky 43 P.O.B 39995
TEL AVIV 6139803 – Israël
Tel: +236 427 11197
Email: info@gadmedical.com
www.gadmedical.com/
SPAIN and PORTUGAL
ACUÑA Y FOMBONA
Marqués de Casa Valdés 103-105
33202 Gijón, Principado de Asturias, España
Tél: +34 985 363 211
Email: afom@acuna-fombona.com
www.acuna-fombona.com
GREECE
IMPACKT
3c Korytsas str
153 54 Glyka Nera – Athens-Greece
Tel: 00302106655429
Fax: 00302167006086
Email: vogdaneris@impackt.gr
PARTNERS
ITEC Services est une CRO qui accompagne Hyprevention dans la conduite des essais cliniques
Sol’iage, association which aims at federating the different stakeholders in the field of gerontechnology and offering a platform for innovative solutions to improve the quality of aging.
BPI France has supported Hyprevention since its creation through grants during the different steps of development of the innovating products and of the company.
Regional Council of Aquitaine has supported Hyprevention since its creation through grants during the different steps of development of the innovating products and of the company.
Aquitaine Regional Incubator – IRA started to support Hyprevention at the stage of the project. During 6 months, IRA has co-financed research and development, allowing Hyprevention to develop his project.
ACCELENCE participates in the clinical study management.
CIC-IT (Clinical Investigation Center – Technological Innovation) helps Hyprevention in its clinical strategy.
